Compared to Estimates, BioMarin (BMRN) Q3 Earnings: A Look at Key Metrics

BioMarin Pharmaceutical (BMRN) reported $776.13 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 4.1%. EPS of $0.12 for the same period compares to $0.91 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $784.4 million, representing a surprise of -1.05%. The company delivered an EPS surprise of +180%, with the consensus EPS estimate being -$0.15.While investors closely watch year-over-year changes in headline numbers -- revenue and ...